PI3K/AKT/mTOR通路
蛋白激酶B
胰岛素
肝细胞
信号转导
生物
原癌基因蛋白质c-akt
癌症研究
细胞生物学
化学
内分泌学
生物化学
体外
作者
Angela Molinaro,Barbara Becattini,Arianna Mazzoli,Augusto Bleve,Lucia Radici,Ingela Maxvall,Victoria Rotter Sopasakis,Antonio Molinaro,Fredrik Bäckhed,Giovanni Solinas
出处
期刊:Cell Metabolism
[Cell Press]
日期:2019-04-11
卷期号:29 (6): 1400-1409.e5
被引量:79
标识
DOI:10.1016/j.cmet.2019.03.010
摘要
Phosphatidylinositol-3-kinase (PI3K) activity is aberrant in tumors, and PI3K inhibitors are investigated as cancer therapeutics. PI3K signaling mediates insulin action in metabolism, but the role of PI3K isoforms in insulin signaling remains unresolved. Defining the role of PI3K isoforms in insulin signaling is necessary for a mechanistic understanding of insulin action and to develop PI3K inhibitors with optimal therapeutic index. We show that insulin-driven PI3K-AKT signaling depends on redundant PI3Kα and PI3Kβ activities, whereas PI3Kδ and PI3Kγ are largely dispensable. We have also found that RAS activity promotes AKT phosphorylation in insulin-stimulated hepatocytes and that promotion of insulin-driven AKT phosphorylation by RAS depends on PI3Kα. These findings reveal the detailed mechanism by which insulin activates AKT, providing an improved mechanistic understanding of insulin signaling. This improved model for insulin signaling predicts that isoform-selective PI3K inhibitors discriminating between PI3Kα and PI3Kβ should be dosed below their hyperglycemic threshold to achieve isoform selectivity.
科研通智能强力驱动
Strongly Powered by AbleSci AI